Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bradenton, Florida Clinical Trials

A listing of Bradenton, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (18) clinical trials

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This study has several treatment arms and each treatment arm has 2 stages. During Stage 1 - AB928 plus zimberelimab alone, AB928 plus zimberelimab with or without a standard of care treatment (enzalutamide or docetaxel), or AB928 plus AB680 with or without zimberelimab will be administered to participants with mCRPC. …

Phase

4.86 miles

Learn More »

Phase I-II FIH TROP2 ADC Advanced Unresectable/Metastatic Solid Tumors Refractory to Standard Therapies

This is an open label, Phase I-II, first in human (FIH) study for SKB264 as monotherapy in patients who have locally advanced unresectable or metastatic solid tumor that is refractory to all standard therapies. TROP2 (trophoblast antigen 2) assessments will not be performed prior to enrollment but it will be …

Phase

4.86 miles

Learn More »

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

This study includes 3 parts: phase 1 (LOXO-305 monotherapy dose escalation and dose expansion), phase 1b (LOXO-305 combination therapy dose expansion), and phase 2 (LOXO-305 monotherapy dose expansion). In phase 1, patients will be enrolled using an accelerated titration design. The starting dose of LOXO-305 in oral tablet form is …

Phase

5.29 miles

Learn More »

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

This is an open-label, Phase I-II, first-in-human (FIH) study for A166 as monotherapy in HER2-expressing patients who progressed on or did not respond to available standard therapies. Patients enrolled in this Phase III study must have documented HER2 positivity defined as positive on in situ hybridization (ISH) or next-generation sequencing …

Phase

5.43 miles

Learn More »

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors

This is a First-in-Human, open-label, multiple ascending dose escalation and dose expansion study of THOR-707 in adult subjects with advanced or metastatic solid tumors. The objectives of the dose escalation phase are to identify the recommended phase 2 dose (RP2D) of THOR-707 as a monotherapy (Part 1) and in combination …

Phase

5.43 miles

Learn More »

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

BT5528 consists of a bicyclic peptide (Bicycle) which binds to EphA2, and is covalently attached to a spacer and a protease cleavable peptide linker attached to MMAE. The Phase I/II multi-center, open-label trial will evaluate BT5528 administered once-weekly as a single agent and in combination with nivolumab. The Phase I …

Phase

5.43 miles

Learn More »

Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer

This a multicenter open-label study comparing safety, tolerability and efficacy of rivoceranib monotherapy, trifluridine/tipiracil monotherapy and the combination of rivoceranib plus trifluridine/tipiracil in subjects with mCRC. Subjects with histologically or cytologically definitive adenocarcinoma of the colon or rectum who have progressed following standard of care therapy for colorectal cancer will …

Phase

5.43 miles

Learn More »

A Study of EDP1503 in Patients With Colorectal Cancer Breast Cancer and Checkpoint Inhibitor Relapsed Tumors

This will be a Phase I/II open-label study which will involve a 2-week monotherapy with EDP1503, following which the patients will be dosed with a combination of EDP1503 and pembrolizumab.

Phase

5.43 miles

Learn More »

A Study of BDTX-189 an Orally Available Allosteric ErbB Inhibitor in Patients With Advanced Solid Tumors.

BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found …

Phase

5.43 miles

Learn More »

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

CONSORTIUM-IO is a first-in-human multicenter, open-label study, where it's main objectives will evaluate: Safety and tolerability of VE800 in combination with Nivolumab Efficacy as measured by a total of overall response rate. The study will enroll approximately 111 patients with melanoma, patients with gastric/gastroesophageal junction (GEJ) adenocarcinoma, and patients with …

Phase

5.43 miles

Learn More »